The stock price of Cue Biopharma Inc (NASDAQ: CUE) has dropped by -17.00 compared to previous close of 1.50. Despite this, the company has seen a fall of -27.62% in its stock price over the last five trading days. zacks.com reported 2024-11-14 that Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.
Is It Worth Investing in Cue Biopharma Inc (NASDAQ: CUE) Right Now?
The 36-month beta value for CUE is also noteworthy at 1.73. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CUE is 62.88M, and at present, short sellers hold a 2.83% of that float. The average trading volume of CUE on November 18, 2024 was 705.47K shares.
CUE’s Market Performance
CUE stock saw an increase of -27.62% in the past week, with a monthly gain of 12.16% and a quarterly increase of 63.82%. The volatility ratio for the week is 19.76%, and the volatility levels for the last 30 days are 19.59% for Cue Biopharma Inc (CUE). The simple moving average for the past 20 days is -23.16% for CUE’s stock, with a -11.00% simple moving average for the past 200 days.
Analysts’ Opinion of CUE
Many brokerage firms have already submitted their reports for CUE stocks, with Jefferies repeating the rating for CUE by listing it as a “Buy.” The predicted price for CUE in the upcoming period, according to Jefferies is $6 based on the research report published on March 13, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CUE reach a price target of $10. The rating they have provided for CUE stocks is “Outperform” according to the report published on June 26th, 2023.
Piper Sandler gave a rating of “Overweight” to CUE, setting the target price at $7 in the report published on November 21st of the previous year.
CUE Trading at 9.33% from the 50-Day Moving Average
After a stumble in the market that brought CUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.68% of loss for the given period.
Volatility was left at 19.59%, however, over the last 30 days, the volatility rate increased by 19.76%, as shares surge +2.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +111.02% upper at present.
During the last 5 trading sessions, CUE fell by -27.62%, which changed the moving average for the period of 200-days by -51.18% in comparison to the 20-day moving average, which settled at $1.6202. In addition, Cue Biopharma Inc saw -52.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CUE
Current profitability levels for the company are sitting at:
- -4.78 for the present operating margin
- -0.18 for the gross margin
The net margin for Cue Biopharma Inc stands at -4.68. The total capital return value is set at -1.63. Equity return is now at value -131.15, with -78.47 for asset returns.
Based on Cue Biopharma Inc (CUE), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -4.02. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -58.76.
Currently, EBITDA for the company is -46.05 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 5.87. The receivables turnover for the company is 3.02for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
In summary, Cue Biopharma Inc (CUE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
